Free Trial

Pluri (PLUR) Competitors

Pluri logo
$5.56 +0.06 (+1.00%)
Closing price 03:59 PM Eastern
Extended Trading
$5.63 +0.06 (+1.17%)
As of 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PLUR vs. ACRS, NVCT, NLTX, MOLN, TIL, BIOA, CGEN, ALEC, GALT, and ACOG

Should you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Aclaris Therapeutics (ACRS), Nuvectis Pharma (NVCT), Neoleukin Therapeutics (NLTX), Molecular Partners (MOLN), Instil Bio (TIL), BioAge Labs (BIOA), Compugen (CGEN), Alector (ALEC), Galectin Therapeutics (GALT), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry.

Pluri vs. Its Competitors

Pluri (NASDAQ:PLUR) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Pluri presently has a consensus price target of $12.00, indicating a potential upside of 115.63%. Aclaris Therapeutics has a consensus price target of $8.71, indicating a potential upside of 449.80%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Pluri.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pluri
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aclaris Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11

Aclaris Therapeutics has a net margin of -732.42% compared to Pluri's net margin of -2,563.29%. Aclaris Therapeutics' return on equity of -30.73% beat Pluri's return on equity.

Company Net Margins Return on Equity Return on Assets
Pluri-2,563.29% -4,191.91% -85.40%
Aclaris Therapeutics -732.42%-30.73%-22.74%

Pluri has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.

16.6% of Pluri shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 25.9% of Pluri shares are owned by insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pluri has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluri$330K132.04-$20.89M-$5.53-1.01
Aclaris Therapeutics$18.72M9.17-$132.07M-$1.39-1.14

In the previous week, Aclaris Therapeutics had 2 more articles in the media than Pluri. MarketBeat recorded 4 mentions for Aclaris Therapeutics and 2 mentions for Pluri. Aclaris Therapeutics' average media sentiment score of 0.77 beat Pluri's score of 0.64 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pluri
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aclaris Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Aclaris Therapeutics beats Pluri on 12 of the 17 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLUR vs. The Competition

MetricPluriMED IndustryMedical SectorNASDAQ Exchange
Market Cap$43.57M$2.96B$5.57B$9.02B
Dividend YieldN/A2.44%5.25%4.03%
P/E Ratio-1.0121.1627.2120.15
Price / Sales132.04260.59416.26185.35
Price / CashN/A41.8337.0657.97
Price / Book5.577.768.085.60
Net Income-$20.89M-$54.96M$3.16B$248.50M
7 Day Performance-3.22%5.99%3.74%5.11%
1 Month Performance13.46%4.41%3.88%7.58%
1 Year Performance1.00%6.36%34.26%21.53%

Pluri Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PLUR
Pluri
3.5132 of 5 stars
$5.57
+1.0%
$12.00
+115.6%
-5.0%$43.57M$330K-1.01150News Coverage
ACRS
Aclaris Therapeutics
2.7988 of 5 stars
$1.42
-3.4%
$9.71
+584.1%
+22.2%$159.17M$18.72M-1.02100Analyst Forecast
Gap Up
NVCT
Nuvectis Pharma
3.2832 of 5 stars
$7.47
-1.1%
$17.00
+127.6%
+28.7%$157.75MN/A-6.618Positive News
NLTX
Neoleukin Therapeutics
N/A$16.16
-2.5%
N/A-44.9%$151.87MN/A-5.2090High Trading Volume
MOLN
Molecular Partners
2.8146 of 5 stars
$3.79
+0.8%
$12.00
+216.6%
-44.3%$151.81M$5.65M-1.97180
TIL
Instil Bio
3.1516 of 5 stars
$20.83
-9.3%
$119.00
+471.3%
+152.5%$150.66MN/A-1.74410
BIOA
BioAge Labs
N/A$4.13
-1.7%
N/AN/A$150.57MN/A0.00N/ANews Coverage
CGEN
Compugen
1.4067 of 5 stars
$1.78
+7.2%
$4.00
+124.7%
-5.1%$148.13M$27.86M-11.1370Positive News
ALEC
Alector
4.0712 of 5 stars
$1.40
-5.4%
$4.00
+185.7%
-65.4%$147.99M$100.56M-1.11270News Coverage
GALT
Galectin Therapeutics
1.1149 of 5 stars
$2.11
-9.4%
$6.00
+184.4%
-5.1%$147.47MN/A-2.939News Coverage
Gap Up
ACOG
Alpha Cognition
1.5021 of 5 stars
$9.33
+2.5%
$20.00
+114.4%
N/A$145.86MN/A-7.77N/A

Related Companies and Tools


This page (NASDAQ:PLUR) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners